Skip to main content

Table 2 Non-compartmental analysis of interferon-α: Mean ± S.D. (CV%)

From: Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model

Group

Dose

Formulation

Cmax(pg/mL)

Median Tmax(h)

AUClast(ng·h/mL)

Controla (N=8)

3 MIU

Roferon-A®

43.27 ± 9.804 (22.66%)

6

0.9664 ± 0.9322 (96.46%)

1 (N=6)

9 MIU

SR-IFN-α

28.33 ± 9.656 (34.08%)

18

2.072 ± 1.134 (54.73%)

2 (N=6)

18 MIU

SR-IFN-α

62.12 ± 15.93 (25.64%)

24

5.373 ± 1.382 (25.72%)

3 (N=6)

27 MIU

SR-IFN-α

65.73 ± 6.702 (10.20%)

24

5.544 ± 0.5509 (9.94%)

4 (N=6)

36 MIU

SR-IFN-α

80.31 ± 9.859 (12.28%)

24

7.151 ± 1.132 (15.83%)

  1. aThere was not a separate control group, but data from a total of eight subjects (two subjects in each of the four groups) who received 3 MIU of Roferon-A® were shown.